Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
MEDTRONIC PLC (NYSE:MDT) offers a strong 3.31% dividend yield, reliable payout history, and solid profitability, making it a compelling choice for dividend investors.
Intuitive Surgical has soared over 150% in three years. But, can the healthcare stalwart overcome tariffs and rising competition to continue winning long-term?
Texas Instruments plans to invest $60 billion to expand U.S. chip manufacturing, creating 60,000 jobs. Apple, Ford, Medtronic, NVIDIA, and SpaceX support the initiative.
The company said its seven factories will span three manufacturing mega-sites and manufacture “hundreds of millions” of U.S.-made chips daily, while creating over 60,000 new U.S. jobs.
PALM BEACH, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report, Grand View Research said that the global diabetic retinopathy market size was estimated at USD 9.48 billion in 2024 and is expected to grow at a CAGR of 6.4% from 2025 to 2030. One of the main factors expected to fuel market expansion is the growing incidence of diabetes in older individuals and the rising prevalence of blindness caused by diabetes. The introduction of novel diagnostic technologies and treatments and the increased awareness are driving the market expansion. The report said: “Diabetes is a globally prevalent health concern. It can result in Diabetic Retinopathy (DR), which is caused by damage to the blood vessels in the retina. DR leads to blurred vision and vision loss in most cases. International Diabetes Federation estimates that 1 in 8 adults will be living with diabetes in 2050. It also states urbanization, an aging population, decreasing physical activity, and the growing prevalence of obesity are some of the key aspects contributing to the rise in type 2 diabetes. DR is a serious microvascular complication of type I and type II diabetes. It is often caused by prolonged high blood sugar levels that damage the blood vessels in the retina. It can progress to sight-threatening stages, which can cause blindness and visual impairment if not treated. According to a report published by the WHO, DR is responsible for 4.8% of the 37 million blindness cases in the world. The prevalence of this condition in the U.S. is expected to increase rapidly. Despite all the necessary measures adopted by the diabetic population, DR can lead to permanent blindness based on the disease stage and severity of the condition. Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tandem Diabetes Care, Inc. (NASDAQ: TNDM), Novo Nordisk A/S (NYSE: NVO), Insulet Corporation (NASDAQ: PODD), Medtronic plc (NYSE: MDT).
As firms continue releasing financial results late into the calendar Q1 earnings season, announcements of dividend increases also continue. Some of the latest announcements are particularly notable. This is because several companies that already have high-dividend yield stocks are increasing their quarterly payments even more.
MEDTRONIC PLC (NYSE:MDT) offers a solid 3.45% dividend yield with a reliable payout history, strong profitability, and reasonable valuation, making it a compelling choice for dividend investors.
United States - 29th May, 2025 - As hernia mesh lawsuits continue to progress against major medical device manufacturers, Mayfair Legal Funding is stepping forward with financial solutions to support plaintiffs awaiting settlements. As a trusted provider of pre-settlement funding, Mayfair is committed to helping victims of defective hernia mesh implants manage their financial needs while pursuing justice.
The company said in a regulatory filing that the decision was made in light of increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new regions.
